Overview

Single Dose Study of PF-06815345 in Healthy Subjects

Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The current study is the first clinical trial proposed with PF-06815345. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single oral doses of PF-06815345 to healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer